BioMidwest
Filter News
Found 73,851 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Some might go as far as to consider the pharmaceutical industry as mankind’s best hope for survival. But now, as the world enters the third year of the pandemic, has that perception changed?
-
In addition to the induction of both mucosal and systemic immunity, advantages of an intranasal approach include the lack of needles, low cost and thermostability under normal refrigeration temperature.
-
Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast
1/26/2022
Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2021, and issued its financial outlook for 2022.
-
IONETIX and PRECISION MOLECULAR Inc. Announce Supply Agreement for Astatine-211
1/26/2022
Agreement secures commerical supply of Astatine-211 to support the clinical development of PMI's targeted alpha therapies.
-
Dynamic Technology Solutions Introduces Self-Diagnostic Tool that Measures Product End-of-Life (EOL) Risk Exposure
1/26/2022
Dynamic Technology Solutions (Dynamic) announced today the introduction of its EOL PrepSM Self-Diagnostic, based on industry best practices, that provides insights into how well a company is managing risks associated with product End-of-Life (EOL).
-
Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
1/26/2022
Panbela Therapeutics, Inc. (Nasdaq: PBLA), today announced the initiation of the company’s global Phase 2 clinical trial of SBP-101 in combination with Gemcitabine and Nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma, which is referred to as the ASPIRE trial.
-
Checkpoint Surgical Enrolls First Patient in Nerve Regeneration Clinical Study
1/26/2022
Checkpoint Surgical, Inc., the leader in intraoperative nerve repair stimulation technology, today announced it has enrolled the first patient in its multi-center clinical study of the company's breakthrough nerve regeneration technology.
-
Surmodics to Webcast First Quarter Fiscal 2022 Earnings Conference Call on February 3
1/26/2022
Surmodics, Inc. today announced that it will host a live webcast of its first quarter fiscal 2022 conference call on Thursday, February 3, at 7:30 a.m. CT (8:30 a.m. ET).
-
Athersys to Host a Virtual Presentation on Its MultiStem® Programs
1/26/2022
Athersys to Host a Virtual Presentation on Its MultiStem ® Programs.
-
200th Treatment Milestone for AIRFLOW-3 COPD Trial
1/25/2022
Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announces two treatment milestones.
-
CinDome Pharma announces successful completion of thorough QT study of CIN-102 (deudomperidone) in healthy subjects.
1/25/2022
CinDome Pharma, Inc. (“CinDome”), a clinical-stage biopharmaceutical company and member of the CinRx Pharma portfolio, today announced the negative results of a clinical thorough QT/QTc study of CIN-102 (deudomperidone) in healthy individuals.
-
Dr. Philip Krause to Provide Strategic Advice to Adjuvance
1/25/2022
Adjuvance Technologies Inc. announced that Philip Krause, MD, will take on a strategic consulting role with the organization as it advances its vaccine development portfolio.
-
AtriCure to Announce Fourth Quarter and Full Year 2021 Financial Results
1/25/2022
AtriCure, Inc. today announced that it will release its fourth quarter and full year 2021 financial results on Tuesday, February 15, 2022.
-
Ocuphire to Host Virtual Investor R&D Day on January 31st
1/25/2022
Ocuphire Pharma, Inc. today announced that it will host a virtual investor R&D Day on Monday, January 31, 2022 from 10:00am to 12:15pm ET.
-
HonorHealth Scottsdale Shea Medical Center Builds Advanced Robotic Program to Treat Heart Rhythm Disorders
1/25/2022
Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that HonorHealth has established a robotic electrophysiology program as part of its Cardiovascular Center of Excellence at HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona.
-
ViewRay® to Participate in the B. Riley Securities Oncology Conference
1/25/2022
ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the B. Riley Securities Oncology Conference.
-
DiaMedica Therapeutics to Present Research at International Stroke Conference
1/25/2022
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the American Heart Association 2022 International Stroke Conference.
-
The U.S. Food and Drug Administration has approved SKYRIZI (risankizumab-rzaa), AbbVie's proposed treatment for adults diagnosed with active psoriatic arthritis (PsA).
-
January has been a largely quiet month for PDUFA dates on the U.S. Food and Drug Administration (FDA)’s calendar. There were two dates for the entire month, and one of those has been moved back to April. Here’s a look.